TA133: Asthma (uncontrolled) - omalizumab
This is a discussion on TA133: Asthma (uncontrolled) - omalizumab within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Asthma (uncontrolled) - omalizumab. It links to the published guidance and key documents. ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
04-01-2010, 12:51 PM
|
|||
|
|||
TA133: Asthma (uncontrolled) - omalizumab
The summary for the published technology appraisal on Asthma (uncontrolled) - omalizumab. It links to the published guidance and key documents.
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA131: Asthma (in children) - corticosteroids | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA138: Asthma (in adults) - corticosteroids | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair) | industry_news | FDA News | 0 | 07-16-2009 03:39 PM |
| Asthma Severity and Perceived Asthma Control Linked With Mortality Risk | industry_news | Other Clinical Pharmacy News | 0 | 09-23-2008 10:45 AM |
| Cough avoidance using ARB in asthma | participant3 | Managed Care Issues for Oral Drugs | 1 | 05-01-2008 08:11 AM |
© 2008 DrugManagementForum™ powered by |
 |